FDA Lifts Holds on “Off-the-Shelf” CAR-T Trials – OncLive
Endpoints News |
FDA Lifts Holds on "Off-the-Shelf" CAR–T Trials
OncLive Cellectis says its “off-the-shelf” allogenic process is faster, easier to develop, and significantly less expensive than autologous CAR T-cell therapy—Novartis has set the price for a one-time treatment with its CAR–T cell therapy, tisagenlecleucel … FDA Lifts Clinical Hold on Cellectis CAR–T Trials FDA lifts clinical hold on Cellectis CAR–T FDA gives Cellectis a green light to relaunch off-the-shelf CAR–T studies — with several strings attached |
